Therefore, breast cancer cell lines BT-474, MCF-7, MDA-361, MDA-436 and SK-BR-3 were treated with these inhibitors to compare transcriptional signatures responsive to both RPS6KB1 and PI3K/mTOR pathway inhibitions. Here, RPS6KB1 is linked to breast carcinoma.